var data={"title":"Hydrocodone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hydrocodone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/223825?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hydrocodone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hydrocodone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50847584\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Opioid-Containing Cough and Cold Medicines Safety Alert</span>\n      <span class=\"collapsible-date\">January 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA is requiring safety labeling changes to prescription opioid-containing cough and cold products to limit use in pediatric patients because the serious risks of these medicines outweigh their potential benefits in this population. Prescription opioid cough and cold medicines containing codeine or hydrocodone will no longer be indicated in children younger than 18 years of age and will be labeled for use in adults only. Labeling for these medications will also be updated for adult use, with an expanded Boxed Warning, to include notification regarding the risks of misuse, abuse, addiction, overdose and death, and slowed or difficult breathing that can result from exposure to codeine or hydrocodone.</p>\n        <p style=\"text-indent:0em;\">More information is available at <a target=\"_blank\" href=\"https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm592109.htm?utm_campaign=01112018_PR_FDA%20acts%20to%20protect%20kids%20from%20serious%20risks%20of%20opioid%20ingredients&utm_medium=email&utm_source=Eloqua&amp;token=fVLOaoTJdAjr5X9CPFOAXT73kszGLXeoes13dA/F6kdwsHrmVhJ9ODNnfB3MqLzSkblG8/Pg1mu48a4nejfY5QdMYZiLBDyetiA7KESPUZOCKIqRxBoqu7iOrOdf6rHc1MRVPkuvHNPIk2ImObt2Kr+smpeosouVP0bax4jyff+xCkxWgA/M00hu77gROCcHpRbpW4gAfmOq2zL/3MXcLYJaN3LZz1aIHEFMRveu50A=&amp;TOPIC_ID=91299\" target=\"_blank\">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm592109.htm?utm_campaign=01112018_PR_FDA%20acts%20to%20protect%20kids%20from%20serious%20risks%20of%20opioid%20ingredients&amp;utm_medium=email&amp;utm_source=Eloqua</a>.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Opioid Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada, in collaboration with manufacturers, will update the Canadian labelling of all prescription opioid products to include the following:</p>\n        <ul>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation for a daily opioid threshold dose for the management of chronic noncancer, nonpalliative pain (which aims to reduce risks of adverse events and overdoses associated with higher doses of opioids);</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation to limit the quantity of opioids prescribed for acute pain (which aims to reduce the duration of use and associated risks of developing dependence and substance use disorder); and</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Clarification of warnings, including those for special populations such as pregnant women and patients with a history of dependence or substance use disorder.</p></li></ul>\n        <p style=\"text-indent:0em;\">Health Canada has prioritized product tables for updating based on risk. The labelling updates for all prescription opioids are expected to be completed in January 2019.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65362a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22457547\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Addiction, abuse, and misuse:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hydrocodone ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient&rsquo;s risk prior to prescribing hydrocodone ER and monitor all patients regularly for the development of these behaviors and conditions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Life-threatening respiratory depression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious, life-threatening, or fatal respiratory depression may occur with use of hydrocodone ER. Monitor for respiratory depression, especially during initiation of hydrocodone or following a dose increase. Instruct patients to swallow hydrocodone ER  whole; crushing, chewing, or dissolving hydrocodone  can cause rapid release and absorption of a potentially fatal dose of hydrocodone.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Accidental ingestion:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Accidental ingestion of even 1 dose of hydrocodone ER, especially by children, can result in a fatal overdose of hydrocodone.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neonatal opioid withdrawal syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prolonged use of hydrocodone ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cytochrome P450 3A4 Interaction:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The concomitant use of hydrocodone ER with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. Monitor patients receiving hydrocodone and any CYP3A4 inhibitor or inducer.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks from concomitant use with benzodiazepines or other CNS depressants:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death<i>.</i> Reserve concomitant prescribing of hydrocodone ER and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Interaction with alcohol (Zohydro ER):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products that contain alcohol while taking hydrocodone ER. The co-ingestion of alcohol with hydrocodone may result in increased plasma levels and a potentially fatal overdose of hydrocodone.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23763840\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Hysingla ER;</li>\n      <li>Zohydro ER</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22457550\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Opioid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23632790\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain management:</b> Oral: <b>Note:</b> Pain relief and adverse events should be assessed frequently. Individually titrate to a dose that provides adequate analgesia and minimizes adverse reactions. Use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Opioid-naive patients</i> <i>or</i> <i>patients who are not opioid tolerant</i>: <b>Note:</b> Single doses &gt;40 mg (Zohydro ER) or &gt;60 mg (Vantrela ER), a total daily dose &ge;80 mg (Hysingla ER), &gt;80 mg (Zohydro ER) or &gt;120 mg (Vantrela ER), and Vantrela ER 90 mg tablets are only for patients who are opioid tolerant. Opioid tolerance is defined as: Patients already taking (for 1 week or more) at least 60 mg of oral morphine daily, 25 mcg of transdermal fentanyl per hour, 30 mg of oral oxycodone daily, 8 mg oral hydromorphone daily, 25 mg oral oxymorphone daily, 60 mg oral hydrocodone or an equivalent dose of another opioid.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hysingla ER: Initial: 20 mg once daily. Dose increases may occur in increments of 10 to 20 mg every 3 to 5 days as needed to achieve adequate analgesia</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Vantrela ER: Initial: 15 mg every 12 hours. Dose increases may occur every 3 to 7 days as needed to achieve adequate analgesia (maximum: 180 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Zohydro ER: Initial: 10 mg every 12 hours. Dose increases may occur in increments of 10 mg every 12 hours every 3 to 7 days as needed to achieve adequate analgesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Conversion from other oral hydrocodone formulations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hysingla ER: Initiate hydrocodone ER with the total daily dose of oral hydrocodone (mg/day) administered once daily. Dose increases may occur in increments of 10 to 20 mg every 3 to 5 days as needed to achieve adequate analgesia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vantrela ER: Initiate hydrocodone ER with the total daily dose of oral hydrocodone (mg/day) divided in half for administration every 12 hours. Dose increases may occur every 3 to 7 days as needed to achieve adequate analgesia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zohydro ER: Initiate hydrocodone ER with the total daily dose of oral hydrocodone (mg/day) divided in half for administration every 12 hours. Dose increases may occur in increments of 10 mg every 12 hours every 3 to 7 days as needed to achieve adequate analgesia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Conversion from other oral opioids (see tables): </i></b>Discontinue all other around-the-clock opioids when hydrocodone ER is initiated. Substantial interpatient variability exists in relative potency and formulations. Therefore, it is safer to underestimate a patient&rsquo;s daily oral hydrocodone requirement and provide breakthrough pain relief with rescue medication (eg, immediate release opioid) than to overestimate requirements. The following approximate oral conversion factors may be used to convert from oral opioid therapy to hydrocodone ER.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">To get the <i>approximate</i> equivalent doses for conversion from current opioid therapy to hydrocodone ER, select the opioid, sum the total daily dose, then multiply by the approximate oral conversion factor to calculate the <i>approximate</i> oral hydrocodone ER daily dose. Initiate with the total daily dose of oral hydrocodone ER (mg/day) once daily (Hysingla ER) or divided in half for administration every 12 hours (Vantrela ER, Zohydro ER). Titrate until adequate pain relief with tolerable side effects has been achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">For patients on more than 1 opioid, calculate the <i>approximate</i> oral hydrocodone dose for each opioid and sum the totals. Always round the dose down, if necessary, to the appropriate hydrocodone ER strength(s) available. Reduce the calculated total daily dose of oral hydrocodone ER dose by 25%. Initiate with the total daily dose of oral hydrocodone ER (mg/day) once daily (Hysingla ER) or divided in half for administration every 12 hours (Vantrela ER, Zohydro ER). Titrate until adequate pain relief with tolerable side effects has been achieved.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Conversion Factors to Hysingla ER</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Previous Oral Opioid</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Approximate Oral Conversion Factor</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Oxycodone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Methadone<sup>1</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.5</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Oxymorphone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hydromorphone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Morphine</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.5</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Codeine</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.15</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Tramadol</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.1</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;text-align:left;\">\n              <sup>1</sup>Monitor closely; ratio between methadone and other opioid agonists may vary widely as a function of previous drug exposure. Methadone has a long half-life and may accumulate in the plasma.</p></td></tr></tbody></table>\n    \n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Conversion Factors to Vantrela ER<sup>1</sup></caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Previous Oral Opioid</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Approximate Oral Conversion Factor<sup>2</sup></p></th></tr></thead>\n      <tfoot>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;text-align:left;\">\n              <sup>1</sup>\n              <i>Approximate</i> equivalent doses for conversion from current opioid therapy to Vantrela ER.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;text-align:left;\">\n              <sup>2</sup>Ratio for converting oral opioid dose to approximate Vantrela ER equivalent dose.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;text-align:left;\">\n              <sup>3</sup>Monitor closely; ratio between methadone and other opioid agonists may vary widely as a function of previous drug exposure. Methadone has a long half-life and may accumulate in the plasma.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;text-align:left;\">\n              <sup>4</sup>Initiate regimen as opioid-naive patients or patients who are not opioid tolerant.</p></td></tr></tfoot>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hydromorphone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Methadone<sup>3</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.5</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Oxymorphone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.5</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Oxycodone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.75</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hydrocodone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.5</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Morphine</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.5</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Codeine</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.075</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Meperidine</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.05</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Tramadol<sup>4</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">None</p></td></tr></tbody></table>\n    \n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Conversion Factors to Zohydro ER<sup>1</sup></caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Previous Oral Opioid</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Approximate Oral Conversion Factor<sup>2</sup></p></th></tr></thead>\n      <tfoot>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>1</sup>\n              <i>Approximate</i> equivalent doses for conversion from current opioid therapy to Zohydro ER.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>2</sup>Ratio for converting oral opioid dose to approximate Zohydro ER equivalent dose.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:-2em;margin-left:2em;\">\n              <sup>3</sup>Monitor closely; ratio between methadone and other opioid agonists may vary widely as a function of previous drug exposure. Methadone has a long half-life and may accumulate in the plasma.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hydrocodone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Oxycodone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Methadone<sup>3</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Oxymorphone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Hydromorphone</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.67</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Morphine</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.67</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Codeine</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.1</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>\n        <b>Conversion from transdermal fentanyl:</b></i> Treatment may be started 18 hours after the removal of the fentanyl transdermal patch. For every fentanyl 25 mcg per hour transdermal patch, initially substitute Hysingla ER 20 mg every 24 hours or Vantrela ER 15 mg every 12 hours or Zohydro ER 10 mg every 12 hours. Monitor patient closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Conversion from transdermal buprenorphine:</i></b>Hysingla ER: Initial: 20 mg every 24 hours in patients receiving &le; 20 mcg/hour buprenorphine transdermal. Monitor patient closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Discontinuation of therapy:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hysingla ER, Vantrela ER: For patients on long term opioid therapy, decrease dose by 25% to 50% every 2 to 4 days; monitor carefully for signs/symptoms of withdrawal. If patient displays withdrawal symptoms, increase dose to previous level and then reduce dose more slowly by increasing interval between dose reductions, decreasing amount of daily dose reduction, or both.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zohydro ER: For patients on long term opioid therapy, gradually titrate the dose downward every 2 to 4 days to prevent signs and symptoms of withdrawal. If patient displays withdrawal symptoms, increase dose to previous level and then reduce dose more slowly by increasing interval between dose reductions, decreasing amount of daily dose reduction, or both.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23632791\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Initiate dosing at the lower end of the dosage range. Monitor closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23632792\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hysingla ER, Vantrela ER:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate to severe impairment: Initial: Start with 50% of the initial dose; titrate carefully; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD): Initial: Start with 50% of the initial dose; titrate carefully; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zohydro ER: There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; initiate therapy with a low dose and monitor closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23632793\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hysingla ER, Zohydro ER: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vantrela ER: Initial: Start with 50% of the initial dose; titrate carefully; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hysingla ER: Initial: Start with 50% of the initial dose; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vantrela ER: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zohydro ER: Initial: 10 mg every 12 hours; monitor closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23763841\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule ER 12 Hour Abuse-Deterrent, Oral, as bitartrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zohydro ER: 10 mg (60 ea); 15 mg (60 ea); 20 mg (60 ea); 30 mg (60 ea); 40 mg (60 ea); 50 mg (60 ea) [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 12 Hour, Oral, as bitartrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zohydro ER: 10 mg [DSC], 15 mg [DSC], 20 mg [DSC], 30 mg [DSC], 40 mg [DSC], 50 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet ER 24 Hour Abuse-Deterrent, Oral, as bitartrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hysingla ER: 20 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hysingla ER: 30 mg, 40 mg, 60 mg, 80 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hysingla ER: 100 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hysingla ER: 120 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23763839\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49411482\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Vantrela ER (hydrocodone bitartrate extended-release tablets): FDA approved January 2017; anticipated availability is currently unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23632725\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22687597\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Hysingla ER: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206627s004lbl.pdf&amp;token=oW31w653mg6k4Bh1FFhaZSTIVXMTgDl2jteXvGKj5N2At6GYOMPFRAoWAg85amTd1RLiRWJFSFKXmaJPGyH6xyMsgVThXfmFncOXHi0XGdQ=&amp;TOPIC_ID=91299\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206627s004lbl.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Vantrela ER: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207975s000lbl.pdf#page=39&amp;token=VMS+JV4PzvPqEWRmRosUsMfReTvoi8TqBDGTdJRq5oWPdIKVphgg/e/ERZsFAIucKj5MJaBHTD6Hkrg9NtNwTnhTVWs/n7RJ8SaMLUTgh/jWsDldWlVmhsQAaqS4dJfw&amp;TOPIC_ID=91299\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207975s000lbl.pdf#page=39</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Zohydro ER: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202880s009s010lbl.pdf#page=28&amp;token=54JvFfEuCY4P/vKa628uoifw6kIsEE/MYcCgtsAU30VGGzTDi25KhEcIJ4yrdZBXTi9SH/yCP9EgJWI6lT7f1oA+FlmNar55ELA1PeSGW7RoG6SvgjgddcJH9RwgQ2cQ&amp;TOPIC_ID=91299\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202880s009s010lbl.pdf#page=28</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23632799\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer whole; do not crush, chew, or dissolve. Crushing, chewing, or dissolving will result in uncontrolled delivery of hydrocodone and can lead to overdose or death. Do not presoak, lick or wet dosage form prior to ingestion. Capsules or tablets should be administered one at a time, with enough water to ensure complete swallowing immediately after placing in the mouth. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22457552\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain management:</b> Management of pain severe enough to require daily around-the-clock opioid, long-term treatment and for which alternative treatment options are inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Reserve hydrocodone ER for use in patients for whom alternative treatment options (eg, nonopioid analgesics, immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Hydrocodone ER is not indicated as an as-needed analgesic.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22457546\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">HYDROcodone may be confused with HYDROmorphone, oxyCODONE, oxymorphone</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23306220\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Constipation (3% to 14%), nausea (7% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (&ge;1% to &lt;5%), peripheral edema (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (6%), chills (&ge;1% to &lt;5%), sedation (&ge;1% to &lt;5%), anxiety (4%), insomnia (3%), dizziness (2% to 3%), drowsiness (1% to 3%), fatigue (2%), depression, falling, lethargy, migraine, pain, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (1%), hyperhidrosis, night sweats, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration, hot flash, hypokalemia, increased gamma-glutamyl transferase, increased serum cholesterol</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (5% to 6%), dyspepsia (&ge;1% to &lt;5%), gastroenteritis (&ge;1% to &lt;5%), upper abdominal pain (&ge;1% to &lt;5%), viral gastroenteritis (&ge;1% to &lt;5%), diarrhea (4%), abdominal pain (3%), decreased appetite (2%), xerostomia (1%), abdominal distress, gastroesophageal reflux disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (4%), muscle spasm (3%), tremor (3%), arthralgia, bone fracture (foot), injury to the joint, joint sprain, limb pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, osteoarthritis, strain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (&ge;1% to &lt;5%), nasal congestion (&ge;1% to &lt;5%), nasopharyngitis (&ge;1% to &lt;5%), oropharyngeal pain (&ge;1% to &lt;5%), sinusitis (&ge;1% to &lt;5%), upper respiratory tract infection (3%), cough, dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever, laceration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Abdominal distention, abnormality in thinking, agitation, altered mental status, anaphylaxis, choking sensation, confusion, decreased libido, drug-induced hypersensitivity, drug withdrawal, dysphagia, edema, erythema, esophageal obstruction, flushing, hypogonadism (Brennan 2013; Debono, 2011), hypotension, hypoxia, increased thirst, intestinal obstruction, irritability, malaise, mood changes, muscle twitching, opioid dependence, orthostatic hypotension, palpitations, pancreatitis, presyncope, prolonged Q-T interval on ECG, respiratory depression, retching, syncope, urinary retention, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22457553\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis) to hydrocodone or any component of the formulation; GI obstruction, including paralytic ileus (known or suspected); significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for opioids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23632732\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: QTc prolongation has been observed with hydrocodone ER following doses of 160 mg/day. Use with caution in patients with heart failure, bradyarrhythmias, electrolyte abnormalities or using other drugs known to prolong the QTc interval. Avoid use in patients with congenital long QT syndrome. If patients develop QTc prolongation, consider dose reduction of 33% to 50% or change to an alternate analgesic.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery, driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Constipation: May cause constipation which may be problematic in patients with unstable angina and patients post-myocardial infarction. Consider preventive measures (eg, stool softener, increased fiber) to reduce the potential for constipation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute myocardial infarction [MI]), or drugs that may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Avoid use in patients with circulatory shock.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene-derivative opioid agonists (codeine, hydromorphone, levorphanol, oxycodone, oxymorphone).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: <b>[US Boxed Warning]: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely for respiratory depression, especially during initiation or dose escalation. Swallow ER capsules or tablets whole; crushing, chewing, or dissolving can cause rapid release and a potentially fatal dose. </b>Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison disease. Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction, infertility, mood disorders, and osteoporosis (Brennan 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction or acute pancreatitis; may cause constriction of sphincter of Oddi.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression/coma: Avoid use in patients with impaired consciousness or coma as these patients are susceptible to intracranial effects of CO<sub>2</sub> retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delirium tremens: Use with caution in patients with delirium tremens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dose adjustment may be needed. Vantrela ER is not recommended in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mental health conditions: Use opioids with caution for chronic pain in patients with mental health conditions (eg, depression, anxiety disorders, post-traumatic stress disorder) due to increased risk for opioid use disorder and overdose; more frequent monitoring is recommended (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Use with caution in patients who are morbidly obese.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Use with caution in patients with toxic psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with moderate to severe renal impairment; dose adjustment may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those having a substantially decreased respiratory reserve, hypoxia, hypercarbia, or preexisting respiratory depression, particularly when initiating therapy and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients with a history of seizure disorders; may cause or exacerbate preexisting seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sleep-disordered breathing: Use opioids with caution for chronic pain and titrate dosage cautiously in patients with risk factors for sleep-disordered breathing, including HF and obesity. Avoid opioids in patients with moderate to severe sleep-disordered breathing (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzodiazepines or other CNS depressants: <b>[US Boxed Warning]: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of hydrocodone ER and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosage and durations to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CYP 3A4 interactions: <b>[US Boxed Warning]: Use with all CYP3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitant CYP 3A4 inducer may result in increased hydrocodone concentrations. Monitor patients receiving hydrocodone ER and any CYP3A4 inhibitor or inducer.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Zohydro ER: <b>[US Boxed Warning]: Do not administer hydrocodone ER with alcoholic beverages or ethanol-containing products because of the risk of increased plasma levels and potentially fatal overdose of hydrocodone.</b> Alcohol may disrupt extended-release characteristic of product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Use opioids for chronic pain with caution in this age group; monitor closely due to an increased potential for risks, including certain risks such as falls/fracture, cognitive impairment, and constipation. Clearance may also be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increasing the risk for respiratory depression or overdose (Dowell [CDC 2016]). Decrease initial dose. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Neonatal withdrawal syndrome: <b>[US Boxed Warning]: Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</b> Signs and symptoms include irritability, hyperactivity and abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, and failure to gain weight. Onset, duration, and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dysphagia/choking: Hysingla ER: Esophageal obstruction, dysphagia, and choking have occurred. Patients with underlying gastrointestinal (GI) disorders (eg, esophageal or colon cancer) with a small GI lumen are at greater risk. Consider the use of alternative analgesics in these patients. Do not presoak, lick, or wet tablets prior to ingestion; take 1 tablet at a time with enough water to ensure complete swallowing immediately after placing in mouth.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse/diversion: <b>[US Boxed Warning]: Use exposes patients and other users to the risks of addiction, abuse, and misuse, potentially leading to overdose and death. Assess each patient&rsquo;s risk prior to prescribing; monitor all patients regularly for development of these behaviors or conditions.</b> Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Other factors associated with increased risk include younger age, concomitant depression (major), and psychotropic medication use. Consider offering naloxone prescriptions in patients with factors associated with an increased risk for overdose, such as history of overdose or substance use disorder, higher opioid dosages (&ge;50 morphine milligram equivalents/day orally), and concomitant benzodiazepine use (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Accidental ingestion: <b>[US Boxed Warning]: Accidental ingestion of even one dose, especially in children, can result in a fatal overdose of hydrocodone.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Chronic pain (outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder) in outpatient setting in adults: Opioids should not be used as first-line therapy for chronic pain management (pain &gt;3-month duration or beyond time of normal tissue healing) due to limited short-term benefits, undetermined long-term benefits, and association with serious risks (eg, overdose, MI, auto accidents, risk of developing opioid use disorder). Preferred management includes nonpharmacologic therapy and nonopioid therapy (eg. NSAIDs, acetaminophen, certain anticonvulsants and antidepressants). If opioid therapy is initiated, it should be combined with nonpharmacologic and nonopioid therapy, as appropriate. Prior to initiation, known risks of opioid therapy should be discussed and realistic treatment goals for pain/function should be established, including consideration for discontinuation if benefits do not outweigh risks. Therapy should be continued only if clinically meaningful improvement in pain/function outweighs risks. Therapy should be initiated at the lowest effective dosage using immediate-release opioids (instead of extended-release/long-acting opioids). Risk associated with use increases with higher opioid dosages. Risks and benefits should be re-evaluated when increasing dosage to &ge;50 morphine milligram equivalents (MME)/day orally; dosages &ge;90 MME/day orally should be avoided unless carefully justified (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: Opioids decrease bowel motility; monitor for decreased bowel motility in postop patients receiving opioids. Use with caution in the perioperative setting; individualize treatment when transitioning from parenteral to oral analgesics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Concurrent use of mixed agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol) or partial agonist (eg, buprenorphine) analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Taper dose gradually when discontinuing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299458\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220858\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=91299&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of HYDROcodone. Alcohol (Ethyl) may increase the serum concentration of HYDROcodone. Management: Patients using the Zohydro ER brand of extended-release hydrocodone must not consume alcohol or alcohol-containing products due to possibly fatal outcomes. Other hydrocodone products are also expected to interact, but to a less significant degree.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alvimopan: Opioid Analgesics may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May enhance the analgesic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the CNS depressant effect of HYDROcodone. Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of HYDROcodone. Specifically, concentrations of hydromorphone may be decreased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of HYDROcodone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of HYDROcodone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of HYDROcodone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of HYDROcodone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Opioid Analgesics may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diuretics: Opioid Analgesics may enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Opioid Analgesics may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Opioid Analgesics may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of HYDROcodone. Management: Consider alternatives to this combination when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: May diminish the therapeutic effect of Opioid Analgesics. Management: Avoid the concomitant use of nalmefene and opioid analgesics. Discontinue nalmefene 1 week prior to any anticipated use of opioid analgesics. If combined, larger doses of opioid analgesics will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naltrexone: May diminish the therapeutic effect of Opioid Analgesics. Management: Seek therapeutic alternatives to opioids.  See full drug interaction monograph for detailed recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, and Ritonavir: May increase the serum concentration of HYDROcodone. Management: Reduce the hydrocodone dose by 50% during concurrent use of ombitasvir, paritaprevir, and ritonavir; monitor closely for both analgesic effectiveness and for signs of toxicity or withdrawal.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of HYDROcodone. Management: Reduce the hydrocodone dose by 50% during concurrent use of ombitasvir, paritaprevir, ritonavir, and dasabuvir; monitor closely for both analgesic effectiveness and for signs of toxicity or withdrawal.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Analgesics. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: Opioid Analgesics may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Opioid Analgesics may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Opioid Analgesics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: May enhance the bradycardic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24528278\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Ethanol may disrupt extended-release characteristics and increase plasma levels of hydrocodone potentially leading to fatal overdose. Management: Do not administer hydrocodone ER with alcoholic beverages or ethanol-containing products.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23632729\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">\n      <b>[U.S. Boxed Warning]: Prolonged maternal use of opioids during pregnancy can cause neonatal withdrawal syndrome in the newborn which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If prolonged opioid therapy is required in a pregnant woman, ensure treatment is available and warn patient of risk to the neonate.</b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Opioids cross the placenta. Maternal use of opioids may be associated with birth defects, poor fetal growth, stillbirth, and preterm delivery (CDC [Dowell 2016]). If chronic opioid exposure occurs in pregnancy, adverse events in the newborn (including withdrawal) may occur (Chou 2009). Symptoms of neonatal abstinence syndrome (NAS) following opioid exposure may be autonomic (eg, fever, temperature instability), gastrointestinal (eg, diarrhea, vomiting, poor feeding/weight gain), or neurologic (eg, high-pitched crying, hyperactivity, increased muscle tone, increased wakefulness/abnormal sleep pattern, irritability, sneezing, seizure, tremor, yawning) (Dow 2012; Hudak 2012). Mothers who are physically dependent on opioids may give birth to infants who are also physically dependent. Opioids may cause respiratory depression and psycho-physiologic effects in the neonate; newborns of mothers receiving opioids during labor should be monitored.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Agents other than hydrocodone are recommended to treat maternal pain during labor and immediately postpartum (ACOG 177 2017) as well as chronic noncancer pain in pregnant women or those who may become pregnant (CDC [Dowell 2016]; Chou 2009; Kahan 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23632731\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Hydrocodone and the active metabolite hydromorphone are present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of hydrocodone (immediate release product) was calculated in one study to be 0.2% to 9% when compared to a weight-adjusted maternal dose of 44 to 423.2 mcg/kg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID is &lt;10 (Anderson 2016; Ito 2000). Cumulative exposure from hydrocodone and hydromorphone should be considered.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of hydrocodone was calculated using milk concentrations of 1.6 to 99.6 mcg/mL, providing an estimated daily infant dose via breast milk of 0.2 to 14.9 mcg/kg/day. These milk concentrations were obtained following maternal administration of oral hydrocodone in combination with acetaminophen. Hydromorphone was also detected in breast milk (range: 0.2 to 86.7 mcg/L), providing a neonatal dose of 2.1 mcg/kg/day (range: 0.03 to 13 mcg/kg/day) (Sauberan 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Grogginess and sleepiness were reported in a mother and breastfeeding infant following maternal use of hydrocodone 10 mg in combination with acetaminophen 650 mg (two tablets every 4 hours) (Bodley 1997). Withdrawal symptoms may occur when maternal use is discontinued or breastfeeding is stopped.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Current guidelines note that nonopioid analgesics are preferred for postpartum pain in breastfeeding women (Montgomery 2012). If hydrocodone is needed, high doses (&ge;10 mg), doses &gt;40 mg/day, or frequent administration should be avoided (Montgomery 2012; Sauberan 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> Information related to hydrocodone and breastfeeding is from studies using short acting products, not the extended release formulation. In addition, maternal CYP2D6 status was not evaluated (Anderson 2007; Sauberan 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When opioids are needed in breastfeeding women, the lowest effective dose for the shortest duration of time should be used to limit adverse events in the mother and breastfeeding infant. In general, a single occasional dose of an opioid analgesic may be compatible with breastfeeding (WHO 2002). Breastfeeding women using opioids for postpartum pain or for the treatment of chronic maternal pain should monitor their infants for drowsiness, sedation, feeding difficulties, or limpness (ACOG 177 2017; Montgomery 2012; Sachs 2013). Withdrawal symptoms may occur when maternal use is discontinued or breastfeeding is stopped. Due to the potential for serious adverse reactions, breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23632801\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pain relief, respiratory and mental status, blood pressure; signs of misuse, abuse, and addiction; signs or symptoms of hypogonadism or hypoadrenalism (Brennan 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alternate recommendations: Chronic pain (long-term therapy outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder): Evaluate benefits/risks of opioid therapy within 1 to 4 weeks of treatment initiation and with dose increases. Re-evaluate benefits/risks every 3 months during therapy or more frequently in patients at increased risk of overdose or opioid use disorder. Urine drug testing is recommended prior to initiation and re-checking should be considered at least yearly (includes controlled prescription medications and illicit drugs of abuse). State prescription drug monitoring program (PDMP) data should be reviewed by clinicians prior to initiation and periodically during therapy (frequency ranging from every prescription to every 3 months) (Dowell [CDC 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23632736\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to opioid receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23632738\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: ~1,300 to 1,400 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 36%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic: O-demethylation via primarily CYP2D6 to hydromorphone (major, active metabolite with ~10- to 33-fold higher or as much as a &gt;100-fold higher binding affinity for the mu-opioid receptor than hydrocodone); N-demethylation via CYP3A4 to norhydrocodone (major metabolite); and ~40% of metabolism/clearance occurs via other non-CYP pathways, including 6-ketosteroid reduction to 6-alpha-hydrocol and 6-beta-hydrocol, and other elimination pathways (eg, fecal, biliary, intestinal, renal) (Hutchinson, 2004; Volpe, 2011; Zhou, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Hysingla ER: ~7 to 9 hours; Vantrela ER: ~11 to 12 hours; Zohydro ER: ~ 8 hours (plasma)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Hysingla ER: 6 to 30 hours; Vantrela ER: ~8 hours; Zohydro ER: ~5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (26% of single dose in 72 hours, with ~12% as unchanged drug, 5% as norhydrocodone, 4% as conjugated hydrocodone, 3% as 6-hydrocodol, and 0.21% as conjugated 6-hydromorphol (Zhou, 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23884124\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 12 Hour Abuse-Deterrent</b> (Zohydro ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (60): $617.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (60): $659.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (60): $680.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (60): $701.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (60): $722.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $753.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet ER 24 Hour Abuse-Deterrent</b> (Hysingla ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (60): $621.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (60): $906.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (60): $1,221.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (60): $1,691.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (60): $2,280.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $2,901.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (60): $3,215.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23670579\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dicodid (SE);</li>\n      <li>Hydrocodon (CH);</li>\n      <li>Hydrokon Naf (NO);</li>\n      <li>Tucodil (SE);</li>\n      <li>Tucodil Mite (SE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abele W. Herbal medication: potential for adverse interactions with analgesic drugs. <i>J Clin Pharm Ther</i>. 2002;27(6)391-401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/12472978/pubmed\" target=\"_blank\" id=\"12472978\">12472978</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins&mdash;Obstetrics. Practice bulletin no. 177: obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2017;129(4):e73-e89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/28333819/pubmed\" target=\"_blank\" id=\"28333819\">28333819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB, Lane JR, Rossi SS. Hydrocodone excretion into breast milk: the first two reported cases. <i>Breastfeed Med</i>. 2007;2(1):10-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/17661614/pubmed\" target=\"_blank\" id=\"17661614\">17661614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bodley V, Powers D. Long-term treatment of a breastfeeding mother with fluconazole-resolved nipple pain caused by yeast: a case study. <i>J Hum Lact</i>. 1997;13(4):307-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/9429366/pubmed\" target=\"_blank\" id=\"9429366\">9429366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3)(suppl 1):S12-S18. doi: 10.1016/j.amjmed.2012.12.001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/23414717/pubmed\" target=\"_blank\" id=\"23414717\">23414717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Broussard CS, Rasmussen SA, Reefhuis J, et al; National Birth Defects Prevention Study. Maternal treatment with opioid analgesics and risk for birth defects. <i>Am J Obstet Gynecol</i>. 2011;204(4):314.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/21345403/pubmed\" target=\"_blank\" id=\"21345403\">21345403</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chou R, Fanciullo GJ, Fine PG, et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. <i>J Pain</i>. 2009;10(2):113-130.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/19187889/pubmed\" target=\"_blank\" id=\"19187889\">19187889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Debono M, Chan S, Rolfe C, Jones TH. Tramadol-induced adrenal insufficiency. <i>Eur J Clin Pharmacol</i>. 2011;67(8):865-867.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/21243342/pubmed\" target=\"_blank\" id=\"21243342\">21243342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dow K, Ordean A, Murphy-Oikonen J, et al; Neonatal Abstinence Syndrome Work Group. Neonatal abstinence syndrome clinical practice guidelines for Ontario. <i>J Popul Ther Clin Pharmacol</i>. 2012;19(3):e488-e506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/23241498/pubmed\" target=\"_blank\" id=\"23241498\">23241498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain&mdash;United States, 2016. <i>MMWR Recomm Rep</i>. 2016;65(1):1-49. doi: 10.15585/mmwr.rr6501e1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/26987082/pubmed\" target=\"_blank\" id=\"26987082\">26987082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hudak ML, Tan RC; Committee On Drugs, Committee on Fetus and Newborn, American Academy of pediatrics. Neonatal drug withdrawal. <i>Pediatrics</i>. 2012;129(2):e540-e560.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/22291123/pubmed\" target=\"_blank\" id=\"22291123\">22291123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. <i>Br J Clin Pharmacol</i>. 2004;57(3):287-297.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/14998425/pubmed\" target=\"_blank\" id=\"14998425\">14998425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hysingla ER (hydrocodone bitartrate) [prescribing information]. Stamford, CT: Purdue Pharma L.P; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahan M, Wilson L, Mailis-Gagnon A, et al, &quot;Canadian Guideline For Safe and Effective Use of Opioids For Chronic Noncancer Pain: Clinical Summary For Family Physicians. Part 2: Special Populations,&quot; <i>Can Fam Physician</i>, 2011, 57(11):1269-76, e419-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/22084456/pubmed\" target=\"_blank\" id=\"22084456\">22084456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery A, Hale TW, Academy Of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2012. <i>Breastfeed Med</i>. 2012;7(6):547-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/23979084/pubmed\" target=\"_blank\" id=\"23979084\">23979084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sauberan JB, Anderson PO, Lane JR, et al. Breast milk hydrocodone and hydromorphone levels in mothers using hydrocodone for postpartum pain. <i>Obstet Gynecol</i>. 2011;117(3):611-617.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/21343764/pubmed\" target=\"_blank\" id=\"21343764\">21343764</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vantrela ER (hydrocodone) [prescribing information]. North Wales, PA: Teva; January 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/21343764/pubmed\" target=\"_blank\" id=\"21343764\">21343764</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Volpe DA, McMahon Tobin GA, Mellon RD, et al. Uniform assessment and ranking of opioid &mu; receptor binding constants for selected opioid drugs. <i>Regul Toxicol Pharmacol</i>. 2011;59(3):385-390.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/21215785/pubmed\" target=\"_blank\" id=\"21215785\">21215785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. <i>Clin Pharmacokinet</i>. 2009;48(12):761-804.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydrocodone-drug-information/abstract-text/19902987/pubmed\" target=\"_blank\" id=\"19902987\">19902987</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zohydro ER (hydrocodone) [prescribing information]. Morristown, NJ: Pernix Therapeutics; December 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 91299 Version 141.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50847584\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F22457547\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F23763840\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F22457550\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F23632790\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F23632791\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F23632792\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F23632793\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F23763841\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F23763839\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F49411482\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F23632725\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F22687597\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F23632799\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F22457552\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F22457546\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F23306220\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F22457553\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F23632732\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299458\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220858\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F24528278\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F23632729\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F23632731\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F23632801\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F23632736\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F23632738\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F23884124\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23670579\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/91299|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hydrocodone-patient-drug-information\" class=\"drug drug_patient\">Hydrocodone: Patient drug information</a></li></ul></div></div>","javascript":null}